U.S. FDA Approves Gilead's Bixlenvo, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
